ConcertAI has acquired CancerLinQ, an oncology-focused real-world information service, from the American Society of Scientific Oncology (ASCO), for an undisclosed quantity.
Cambridge, Mass.-based ConcertAI is a for-profit firm targeted on oncology real-world information, digital-accelerated scientific trial options, and scientific synthetic intelligence imaging interpretation. The nonprofit ASCO represents almost 50,000 oncology professionals who look after folks residing with most cancers.
A narrative in Most cancers Letter famous that ConcertAI, by way of a predecessor agency referred to as Precision Well being AI, has been working with ASCO for 5 years, curating and licensing the info in CancerLinQ.
Most cancers Letter writer Paul Goldberg requested if the practices that offered information to ASCO, a nonprofit, would now present the info to a for-profit entity working in a aggressive market.
“I hope so, as a result of I feel that their expertise—the worth they understand from their engagement—goes to turn out to be a greater one,” ASCO’s Chief Government Officer Clifford Hudis, M.D. responded. “I don’t wish to communicate for no matter ConcertAI could select to do with CancerLinQ, however I feel that the standard of the companies that they obtain ought to quickly enhance.”
Together with the acquisition, ASCO will preserve a multi-year cooperation settlement with CancerLinQ, which was launched by ASCO in 2013. ConcertAI stated the brand new enterprise will improve and develop CancerLinQ’s use of real-world information, analytics, next-generation AI, and different applied sciences to enhance most cancers care and pace scientific analysis.
CancerLinQ represents one of many largest oncology real-world information and high quality of care know-how companies entities on the planet, bringing collectively scientific information from most main EHR techniques. With a community of greater than 100 most cancers facilities and oncology practices, 10 EHR system integrations, and information from almost seven million affected person data, CancerLinQ empowers oncology care groups and researchers with know-how and information improvements to enhance care and speed up most cancers analysis.
CancerLinQ will stay targeted on high quality and advancing the rules of precision medication, increasing real-world information for a broader set of analysis functions, and supporting a brand new scientific trials initiative evolving from CancerLinQ’s TriaLinQ ideas. CancerLinQ will work carefully with ASCO to prioritize the wants of oncology practices and assist the enlargement of the observe community.
“We consider this settlement will present the sources to meet and amplify CancerLinQ’s impression, whereas permitting ASCO to harness the CancerLinQ platform for high quality enchancment initiatives and CancerLinQ Discovery information for analysis to assist our mission,” stated ASCO’s Hudis in a press release. “We count on CancerLinQ to be an essential avenue for practices to realize certification beneath ASCO’s just lately launched ASCO Licensed program.”
“CancerLinQ could also be one of the essential oncology networks in existence. We’re happy and privileged to have the ability to advance the unique high quality enchancment objectives and follow-on analysis pursuits of CancerLinQ in collaboration with ASCO, with urgency and alacrity,” stated Jeff Elton, Ph.D., CEO of ConcertAI, in a press release. “We’re committing greater than $250 million to the standard options, information options, and novel scientific trial options over the approaching few years to realize the very best high quality care, speed up wanted new biomedical improvements, and guarantee the very best outcomes for sufferers.”
ConcertAI will collaborate with ASCO to considerably improve the worth of CancerLinQ for oncology practices and their sufferers by:
• Bolstering SmartLinQ to incorporate new information sources alongside the sturdy scientific information presently obtainable
• Making scientific trials participation extra accessible and fewer burdensome by way of ConcertAI’s Digital Entry to Scientific Trial (DACT) platform
• Growing extra sturdy scientific choice assist inside SmartLinQ
• Supporting automated EHR integration, bringing SmartLinQ seamlessly into practices’ workflows
“The scope and scale of what CancerLinQ and ConcertAI can accomplish collectively is unprecedented,” stated Eric P. Winer, M.D., chair of the board of ASCO, in a press release. “We’ve efficiently constructed a real-world information platform that delivers actionable insights to the most cancers group – and now CancerLinQ is poised to maintain and enhance its impression for oncology practices and sufferers for the long run.”
